Revance Therapeutics traded at $4.67 this Tuesday April 9th, increasing $0.22 or 4.94 percent since the previous trading session. Looking back, over the last four weeks, Revance Therapeutics gained 25.40 percent. Over the last 12 months, its price fell by 85.16 percent. Looking ahead, we forecast Revance Therapeutics to be priced at 4.63 by the end of this quarter and at 4.52 in one year, according to Trading Economics global macro models projections and analysts expectations.